Literature DB >> 24328682

Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis.

Yun Ji1, Ying Zhan, Cuihua Jiang, Xiao Jiang, Meng Gao, Wei Liu, Yue Li, Junhu Wang, Qingqing Wang, Marlein Miranda Cona, Nan Yao, Xiaoning Wang, Zhijun Fang, Zhiqi Yin, Jian Zhang, Ziping Sun, Yicheng Ni.   

Abstract

Hypericin (Hyp) is newly recognized as a necrosis avid agent, but its poor solubility imposes a great hindrance in clinical application. The aim of this paper was to explore sodium cholate (NaCh) as a potential solvent for Hyp and assess the targetability of (131)I-Hyp in rat necrosis models. Hyp solubility in NaCh solutions was evaluated by equilibrium solubility measurement. Biodistribution of (131)I-Hyp in NaCh solutions and mixed organic solvents was investigated in rat models of liver and muscle necrosis examined with MRI and SPECT/CT in vivo. In addition, pharmacokinetics of (131)I-Hyp in NaCh solutions was studied in healthy rats. Results showed NaCh could improve Hyp solubility and (131)I-Hyp incubated in NaCh solutions/rat plasma was stable up to 120 h. On SPECT/CT images at 24 h post injection, liver infarction location appeared as hot spots. Liver necrosis-to-liver ratios were 12.2, 10.0, 9.6 and 8.2 in 60, 15, 2 mmol/L of NaCh solutions and organic solvents, and muscle necrosis-to-liver ratios were 11.1, 10.1, 7.7 and 7.4, respectively. Pharmacokinetics study revealed t(1/2)z (11.93, 8.96 h, p > 0.05) and AUC (0-∞) (421.21, 553.34 MBq/L h, p < 0.05) of (131)I-Hyp in 2, 60 mmol/L of NaCh solutions, respectively. In conclusion, NaCh was an effective cosolvent, and the necrosis avidity of NaCh-dissolved (131)I-Hyp/Hyp was demonstrated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24328682     DOI: 10.3109/1061186X.2013.867962

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Biliary and duodenal drainage for reducing the radiotoxic risk of antineoplastic 131I-hypericin in rat models.

Authors:  Yue Li; Cuihua Jiang; Xiao Jiang; Ziping Sun; Marlein Miranda Cona; Wei Liu; Jian Zhang; Yicheng Ni
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-07

2.  Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis.

Authors:  Xiaojun Qi; Haibo Shao; Jian Zhang; Ziping Sun; Yicheng Ni; Ke Xu
Journal:  Radiol Med       Date:  2014-07-11       Impact factor: 3.469

3.  The combined therapeutic effects of 131iodine-labeled multifunctional copper sulfide-loaded microspheres in treating breast cancer.

Authors:  Qiufang Liu; Yuyi Qian; Panli Li; Sihang Zhang; Zerong Wang; Jianjun Liu; Xiaoguang Sun; Michael Fulham; Dagan Feng; Zhigang Chen; Shaoli Song; Wei Lu; Gang Huang
Journal:  Acta Pharm Sin B       Date:  2018-04-07       Impact factor: 11.413

Review 4.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

5.  Updated developments on molecular imaging and therapeutic strategies directed against necrosis.

Authors:  Dongjian Zhang; Meng Gao; Qiaomei Jin; Yicheng Ni; Jian Zhang
Journal:  Acta Pharm Sin B       Date:  2019-02-13       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.